

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA lifileucel for previously treated unresectable or metastatic melanoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|--|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| <p>During the scoping process, the following issues were identified:</p> <ul style="list-style-type: none">• Geographic deliverability of lifileucel would need to be considered for equality of access.• Young people are less likely to be included in clinical trials. <p>It was noted that access to specialist centres is an implementation issue that cannot be addressed by a NICE evaluation recommendation. It is beyond the committee's remit to consider equality in clinical trial recruitment.</p> |
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| <p>The same equality issues identified during the scoping process were raised.</p> <p>The following additional potential issues were identified:</p> <ul style="list-style-type: none">• The suitability of lifileucel for people with a learning or physical disabilities will need to be considered carefully to ensure lifileucel would be offered when appropriate |

- Lfileucel is unsuitable for women, trans men and non-binary people who are pregnant
- Lfileucel is unsuitable for some older, frailer people
- People under 18 may receive the same potential benefit as was observed in people over 18

The committee noted that its recommendation does not restrict access to treatment for some people over others, the committee agreed the recommendation did not lead to any equalities issues.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
--

Yes, section 3.18

Approved by Principal Technical Adviser (name): Lizzie Walker

Date: 27/11/2025